Search company, investor...

Predict your next investment

Venture Capital
agentcapital.com

Investments

31

Portfolio Exits

8

Funds

2

About Agent Capital

Agent Capital is a health care venture capital firm focused on investing in therapeutics and technology platforms that address the unmet patient need.

Headquarters Location

1400 Main Street, Floor 1

Waltham, Massachusetts, 02451,

United States

(617) 340-2538

Want to inform investors similar to Agent Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Agent Capital News

Healthcare Private Placement and M&A Transactions Review Week Ending April 30, 2023

May 4, 2023

Strategy | Financing Highlight Private Placement / Financing Transactions Orbital Therapeutics: The company raised $270 million of Series A venture funding in a deal led by ARCH Venture Partners on April 26, 2023. Alexandria Venture Investments, Heritage Medical Systems, Exor, The Invus Group, Moore Strategic Ventures, iGlobe Partners, Andreessen Horowitz, Newpath Partners, Agent Capital, Rellim Capital Management, Abu Dhabi Growth Fund, Redmile Group, Casdin Capital and other undisclosed investors also participated in the round. The company is a developer of an RNA therapeutics platform designed to integrate a critical mass of both established and emerging technologies and delivery mechanisms. Vedanta Biosciences: The company raised $106.5 million through a combination of debt and Series D venture funding in a deal led by AXA Investment Managers and AMR Action Fund on April 25, 2023, putting the company’s pre-money valuation at $450 million. Pfizer, Fosun Health Capital, Atlantic Neptune, K2 HealthVentures, Korea Investment Partners, Skyviews Life Science, PEAK6 Strategic Capital, Fiscus Ventures, Hambro Perks, PureTech Health, Seventure Partners, Bill & Melinda Gates Foundation, Revelation Partners, QUAD Investment Management, Magnetar Capital, Verition Fund Management, Reimagined Ventures and Korea Investment Holdings Company also participated in the round. The company is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. Foresight Diagnostics: The company raised $58.8 million of Series B venture funding in a deal led by Foresite Capital Management on April 27, 2023. Civilization Ventures, Bluebird Ventures, Pear, Agent Capital, Leland Stanford Junior University and University of Colorado also participated in the round. The company is a developer of a novel diagnosis technology designed to detect cancers earlier from a simple blood sample. Antiva Biosciences: The company raised $53 million of Series E venture funding in a deal led by MPM Capital on April 27, 2023. GV, Canaan Partners, Sofinnova Investments, Lumira Ventures and Adjuvant Capital also participated in the round. The company is a developer of small molecule antivirals designed to improve health outcomes for patients suffering from diseases caused by HPV and other viruses. Adcentrx Therapeutics: The company raised $38 million of Series A venture funding in a deal led by Eight Roads on April 25, 2023. ABio-X, F-Prime Capital, Delta Capital, Trinity Innovation Fund and other undisclosed investors also participated in the round. The company is an operator of a biotechnology business focused on protein conjugate therapeutics for cancer and other life-threatening diseases. Therini Bio: The company raised $36 million of Series A venture funding in a deal led by MRL Ventures Fund, Sanofi Ventures and Dementia Discovery Fund on April 27, 2023. Foundation For a Better World, Eli Lilly, Dolby Family Ventures, and Alzheimers Drug Discovery Foundation also participated in the round. The company is developing potential treatments to protect the nervous system from multiple sclerosis damage. Pattern BioSciences: The company raised $28.7 million of Series C venture funding in a deal led by Omnimed Capital and Illumina Ventures on April 28, 2023. AMR Action Fund and Daleshaw also participated in the round. The company is a developer of a biotechnology platform designed for cancer treatment. Mend: The company raised $10.5 million of venture funding from undisclosed investors on April 24, 2023. The company is a developer of clinical nutritional products. Rhapsody (Boston): The company received $4.9 million of development capital from undisclosed investors on April 26, 2023. The company is a developer of healthcare integration software intended for federal government organizations as well as public and private hospitals. M&A Transactions Provention Bio / Sanofi: The company was acquired by Sanofi for $2.9 billion on April 27, 2023. Provention Bio Inc is a clinical-stage biopharmaceutical company. Cardiovascular Systems / Abbott: The company was acquired by Abbott for $890 million on April 27, 2023. Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Haystack Oncology / Quest Diagnostics: The company reached a definitive agreement to be acquired by Quest Diagnostics for $300 million on April 27, 2023. The company is a developer of a liquid biopsy diagnostic technology designed to optimize treatment strategies and improve outcomes for patients with cancer. HDL Therapeutics / Swiftmerge Acquisition: The company reached a definitive agreement to be acquired by Swiftmerge Acquisition through a reverse merger, resulting in the combined entity trading on the NASDAQ Stock Exchange under the ticker symbol IVCP as of April 24, 2023. The company is an operator of a commercial-stage biotechnology company intended to fight heart disease. BlackSwan Vascular / China Grand Pharmaceutical and Healthcare Holdings: The company reached a definitive agreement to be acquired by China Grand Pharmaceutical and Healthcare Holdings for $37.5 million on April 24, 2023. The company is a developer of liquid embolic products tailored for use in peripheral vascular applications. Aveva Drug Delivery Systems / DifGen Pharmaceuticals: The company, a subsidiary of Apotex was acquired by DifGen Pharmaceuticals for an undisclosed amount on April 24, 2023. The company is a developer and manufacturer of transdermal drug delivery systems and oral dissolvable films based in Miramar, Florida. Source: Pitchbook Data, Inc.

Agent Capital Investments

31 Investments

Agent Capital has made 31 investments. Their latest investment was in Foresight Diagnostics as part of their Series B on April 4, 2023.

CBI Logo

Agent Capital Investments Activity

investments chart

Agent Capital Portfolio Exits

8 Portfolio Exits

Agent Capital has 8 portfolio exits. Their latest portfolio exit was Carisma Therapeutics on March 07, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/7/2023

Reverse Merger

$99M

3

10/29/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/8/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

9/15/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/3/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/7/2023

10/29/2021

10/8/2021

9/15/2021

6/3/2020

Exit

Reverse Merger

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Agent Capital Fund History

2 Fund Histories

Agent Capital has 2 funds, including Agent Capital Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/21/2021

Agent Capital Fund II

$53M

1

11/20/2019

Agent Capital Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

5/21/2021

11/20/2019

Fund

Agent Capital Fund II

Agent Capital Fund I

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$53M

$99M

Sources

1

10

Agent Capital Team

1 Team Member

Agent Capital has 1 team member, including current Founder, Managing Partner, Geeta Vemuri.

Name

Work History

Title

Status

Geeta Vemuri

Founder, Managing Partner

Current

Name

Geeta Vemuri

Work History

Title

Founder, Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.